Skip to main content

Table 3 Best response to treatment and durability of response (response-evaluable population)

From: Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

  Bortezomib-rituximab (N=96) Rituximab (N=95) Odds ratio (95% CI) P-value
ORR, n (%) 57 (59) 35 (37) 0.399
(0.223, 0.715)
0.002
CR/CRu*, n (%) 12 (13) 6 (6) 0.472
(0.169, 1.314)
0.145
PR, n (%) 45 (47) 29 (31)
Stable disease, n (%) 24 (25) 32 (34)
Progressive disease, n (%) 15 (16) 28 (29)
Durable (≥6 months) response, n (%) 43 (45) 25 (26) 0.440
(0.240, 0.809)
0.008
Median DOR, months 10.4 12.1
Median DOR (CR/CRu*), months 16.5 10.5
  1. *Radiologic CR/CRu verified by bone marrow and lactate dehydrogenase.
  2. CI, confidence interval; CR, complete response; CRu, unconfirmed CR; DOR, duration of response; ORR, overall response rate; PR, partial response.